RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Persistence and Compliance among US Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma
DaCosta Byfield, S., McPheeters, J., Burton, T., Nagar, S., & Hackshaw, MI. (2015). Persistence and Compliance among US Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma. Journal of Managed Care Pharmacy, 21(6), 515 - 22.